Ann: Investor Webinar, page-67

Very impressive all round imo.

I was a bit taken aback by Paul's answer to the first question. Many more Q's of funding than I expected and left with a definite impression that the pathway to funding they've foreshadowed for sometime, that nobody has beleived, is in fact shaping up as a likely outcome. Perhaps with a SPP to make up the diference.

I do wonder how Donna can square the answer about placebo effect with the talk of facilitating NFL allumni participation in trials however. You'd think these participants may be already somewhat compromised by the establishment and promotion of the partnership.